Vis enkel innførsel

dc.contributor.authorBolme, Stine
dc.contributor.authorAusteng, Dordi Kristine
dc.contributor.authorMorken, Tora Sund
dc.contributor.authorFollestad, Turid
dc.contributor.authorHalsteinli, Vidar
dc.date.accessioned2023-10-11T10:31:27Z
dc.date.available2023-10-11T10:31:27Z
dc.date.created2023-03-31T12:28:25Z
dc.date.issued2023
dc.identifier.issn1472-6963
dc.identifier.urihttps://hdl.handle.net/11250/3095763
dc.description.abstractBackground Anti-vascular endothelial growth factor is a medicine administered intravitreally by an injection to maintain visual acuity in patients with a variety of retinal diseases. The demand for this treatment has grown considerably in the westernized world the last two decades and will continue to increase due to an aging population. Because of the high volume, injections seize enormous resources and represent high costs for both hospitals and society. Task-shifting of injections from physicians to nurses may be a means to reduce such costs, however the magnitude of possible savings has been poorly investigated. To this end we investigated changes in the hospital costs per injection, six-year cost projections of physician- versus nurse-administered injections for a Norwegian tertiary hospital and we compared the societal costs per patient per year. Methods Patients (n = 318) were randomized to either physician- or nurse administered injections, and data were prospectively collected. Hospital costs per injection were calculated as the sum of training costs, personnel time and running expenses. The number of injections for the years 2014 – 21 from a Norwegian tertiary hospital was combined with age group specific injection prevalence and population projections to calculate cost projections for 2022 – 27. Societal costs per patient were calculated as the sum of hospital costs, transport costs for patients, caregivers’ use of time, costs of ophthalmology consultations and community-based homecare. Results The hospital costs per injection were 5.5 € higher for physicians compared to nurses (281.6 € versus 276.1 €). Cost projections estimated an annual hospital saving of task-shifting of 48 921 € for 2022 – 27. Societal costs per patient did not differ significantly between the two groups (mean 4988 € vs 5418 €, p = 0.398). Conclusion Task-shifting of injections from physicians to nurses can reduce hospital costs and increase the flexibility of physician resources. The annual savings are modest, but increased demand for injections might increase future cost savings. To achieve future savings for society, organizing ophthalmology consultations and injections on the same day to reduce the number of visits might be a solution.en_US
dc.language.isoengen_US
dc.publisherBioMed Central Ltden_US
dc.rightsNavngivelse 4.0 Internasjonal*
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/deed.no*
dc.titleCost consequences of task-shifting intravitreal injections from physicians to nurses in a tertiary hospital in Norwayen_US
dc.title.alternativeCost consequences of task-shifting intravitreal injections from physicians to nurses in a tertiary hospital in Norwayen_US
dc.typePeer revieweden_US
dc.typeJournal articleen_US
dc.description.versionpublishedVersionen_US
dc.source.volume23en_US
dc.source.journalBMC Health Services Researchen_US
dc.identifier.doi10.1186/s12913-023-09186-0
dc.identifier.cristin2138849
dc.source.articlenumber229en_US
cristin.ispublishedtrue
cristin.fulltextoriginal
cristin.qualitycode2


Tilhørende fil(er)

Thumbnail

Denne innførselen finnes i følgende samling(er)

Vis enkel innførsel

Navngivelse 4.0 Internasjonal
Med mindre annet er angitt, så er denne innførselen lisensiert som Navngivelse 4.0 Internasjonal